The goal of the Innate Immune Receptors and Adjuvant Discovery Program is to protect the human population from infectious disease by establishing a pipeline of new adjuvant leads that exploit the natural capacity of the innate immune system to initiate and sustain appropriate B and T cell responses. Adjuvants will be studied in conjunction with vaccines against NIAID Category A, B, or C Priority Pathogens.
